Novo Nordisk reported an 8.5 per cent increase in revenues to 22.25bn kroner (€3bn) and profit up a little over 1 per cent to 6.5bn kroner in the third quarter, a little head of analyst ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin ... have sent a letter (PDF) to Novo Nordisk to request more ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. The regulatory reprimand ...

contain nutrients that promote healthy aging. Meal planning can help you add healthy aging foods to your daily diet and ...

The history of Novo Nordisk dates back to the time when insulin was discovered. In 1922, the Danish physiologist August Krogh met with to-be fellow Nobel Prize laureates Frederick Grant Banting ...

All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of Wednesday, raising the ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...

Novo Nordisk A/S, a leader in global healthcare, has been actively executing a share repurchase program, buying back B shares as part of a larger DKK 20 billion repurchase initiative set to span ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up. Less than a ...